Royal Sussex County Hospital First in the UK to Enroll a Patient in the Gore REDUCE Clinical Study for the Indication of Patent Foramen Ovale (PFO) Closure

01 November 2011 - International study to demonstrate safety, effectiveness of GORE® HELEX® Septal Occluder for PFO closure in patients with a history of cryptogenic stroke
Gore Acquires Intellectual Property of NMT Medical, Inc.

19 October 2011 - CLOSURE I Trial Data May Create Better Clinical Understanding of Patent Foramen Ovale (PFO) in Stroke Patients
Gore Receives Zero Reports of Erosion Associated With GORE® HELEX® Septal Occluder

22 August 2011 - W. L. Gore & Associates (Gore) today reported that it has received zero accounts of erosion of the aortic root or the free wall of the atrium associated with the worldwide use of the GORE® HELEX® Septal Occluder.
Clinical Investigators Address Confusion Over Study of Patent Foramen Ovale (PFO) in Stroke Patients

13 December 2010 - W. L. Gore & Associates today released the following statement from the Gore REDUCE Clinical Study Principal Investigators on behalf of the Gore REDUCE Clinical Study Steering Committee in response to the recent CLOSURE I results presentation.
Gore Reaffirms Commitment to Stroke Study, Launches Online Resource

15 November 2010 - Cardiology and Neurology Investigators Support Continued Study of Patent Foramen Ovale (PFO)
Gore Provides Update on Patent Foramen Ovale (PFO) Stroke Study

08 July 2010 - Gore Reaffirms Commitment to Multi-National, Randomized Study on PFO Closure in Stroke Patients using GORE® HELEX Septal Occluder Versus Medical Management
Rush University Medical Center First to Enroll Patient in the Gore REDUCE Clinical Study for the Indication of Patent Foramen Ovale (PFO) Closure

11 December 2008 - Multi-national trial to demonstrate safety, effectiveness of GORE HELEX Septal Occluder for PFO closure in patients with a history of cryptogenic stroke
Gore Receives Approval from FDA for Unique Patent Foramen Ovale Stroke Study

05 May 2008 - Multinational trial randomizes stroke patients with Patent Foramen Ovale (PFO) to closure with the GORE HELEX Septal Occluder versus medical management
FDA Approves GORE HELEX Septal Occluder for Treatment of Atrial Septal Defect

03 October 2007 - W. L. Gore & Associates today announced that the US Food & Drug Administration (FDA) granted approval for the GORE HELEX Septal Occluder with modified catheter delivery system indicated for the transcatheter closure of atrial septal defect (ASD).